These results provide strong evidence that MMPs actively contribute to DUX4-induced muscle pathology and support the therapeutic potential of pan-MMP inhibition in mitigating mild pathological features of FSHD. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.